Relevant to this educational activity, James F. Howard, Jr., MD, has financial relationships with ineligible companies. Dr. Howard also intends to discuss the off-label use of a commercial product or device and has agreed to clearly identify any such use to learners.
Des Moines University Medicine and Health Sciences (DMU) is committed to ensuring that accredited continuing education serves the needs of patients and the public. Learners must receive accurate, balanced, and scientifically justified recommendations and be able to trust that accredited continuing education supports safe, effective, cost-effective, and compassionate care based on best practices and evidence.
Prior to the educational activity, DMU implemented the following strategies to mitigate Dr. Howard’s relevant financial relationships and ensure the education is fair, balanced, and free from commercial bias:
- Mitigated all relevant financial relationships through peer review by individuals without relevant financial relationships or through attestation to adherence to evidence-based guidelines for clinical recommendations.
- Reviewed Dr. Howard’s presentation materials and any associated handouts, case studies, and educational materials for commercial bias.
- Required the use of generic names whenever possible and the avoidance of promotional language or product endorsement.
- Ensured that any discussion of investigational or off-label uses is clearly identified as such.
- Disclosed Dr. Howard’s relevant financial relationships to learners prior to the educational activity, along with the mitigation measures implemented by DMU.
If you have any concerns or questions regarding Dr. Howard's presentation or disclosures, please email Dr. Vanessa Gray, Director of the DMU CME Program.
- AbbVie Inc.
- Self-Managed Stock Shareholder
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Ad Scientiam
- Grants or Research Support
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Alexion AstraZeneca Rare Disease
- Grants or Research Support
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Amgen (Horizon Therapeutics plc, Viela Bio)
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Argenx
- Grants or Research Support
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Biohaven Ltd.
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Bristol Meyer Squibb
- Self-Managed Stock Shareholder
- The financial relationship has ended.
- Cartesian Therapeutics
- Grants or Research Support
- Consultant
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Curie.bio
- Consultant
- Scientific Advisor
- The financial relationship has ended.
- Flerie AB (formerly Toleranzia AB)
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- GlaxoSmithKline
- Self-Managed Stock Shareholder
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Hansa Biopharma
- Consultant
- Scientific Advisor
- The financial relationship has ended.
- Japan Tobacco Company
- Consultant
- Scientific Advisor
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Johnson & Johnson
- Self-Managed Stock Shareholder
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Kyverna Therapeutics
- Consultant
- Scientific Advisor
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- F. Hoffmann-LaRoche Ltd
- Consultant
- Scientific Advisor
- The financial relationship has ended.
- Merck EMD Serono
- Grants or Research Support
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- NMD Pharma
- Grants or Research Support
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Novartis
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Pfizer
- Self-Managed Stock Shareholder
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Regeneron Pharmaceuticals
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Seismic Therapeutics
- Consultant
- Scientific Advisor
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- TG Therapeutics
- Consultant
- Scientific Advisor
- The financial relationship has ended.
- UCB Biosciences
- Grants or Research Support
- Consultant
- Advisory Board Member
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Vor Biopharma
- Grants or Research Support
- Consultant
- Scientific Advisor
- The financial relationship has not ended, and it is relevant to the content of the educational activity.
- Vertex
- Consultant
- Scientific Advisor
- The financial relationship has not ended, and it is relevant to the content of the educational activity.